Vimarsana
Biggest News Aggregation in the World

Page 9 - Roxana Mehran News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roxana Mehran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roxana Mehran Today - Breaking & Trending Today

ABILITY DIABETES GLOBAL - A Landmark RCT in the field of PCI for patients with DM, completes Enrolment - Vimarsana News

ABILITY DIABETES GLOBAL - A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

/PRNewswire/ -- ABILITY DIABETES-GLOBAL (ADG), is the World's largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing...

Business News | ABILITY DIABETES GLOBAL - A Landmark RCT in the Field of PCI for Patients with DM, Completes Enrolment - Vimarsana News

Business News | ABILITY DIABETES GLOBAL - A Landmark RCT in the Field of PCI for Patients with DM, Completes Enrolment

Get latest articles and stories on Business at LatestLY. ABILITY DIABETES-GLOBAL (ADG), is the World's largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting stent, Abluminus DES+ (Concept Medical Inc.) with the XIENCE family of DES (Abbott Cardiovascular). Business News | ABILITY DIABETES GLOBAL - A Landmark RCT in the Field of PCI for Patients with DM, Completes Enrolment.

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients - Vimarsana News

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

The results didn’t meet superiority criteria, but researcher Pablo Salinas says he would be “happy with both stents.”

Source: tctmd.com
Cre8 EVO Stent Loses Sweet Spot in Diabetes at 2 Years: SUGAR - Vimarsana News

Cre8 EVO Stent Loses Sweet Spot in Diabetes at 2 Years: SUGAR

Outcomes once deemed "almost too good to be true" disappeared with longer follow-up in an all-comer population of patients with diabetes undergoing revascularization.

Add PCSK9 Inhibitors to Statins at Primary PCI: EPIC-STEMI - Vimarsana News

Add PCSK9 Inhibitors to Statins at Primary PCI: EPIC-STEMI

The powerful LDL-lowering agents aren't being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.